Riboxx develops customized and tailor-made molecular tools for gene silencing in vitro and in vivo through RNA interference: small interfering RNA (siRNA) and microRNA (miRNA).
The company therefore has two divisions. Riboxx Life Sciences makes RNA based products for the industry (read our review on the value of mRNA in Biotech).
Riboxx Pharmaceuticals, on the other hand, is developing immunomodulators for therapeutic vaccines (against cancer) and prophylactic vaccines (against infections).
Toll-Like Receptors (TLRs) are pattern recognition receptors implicated in the innate immune response. They are also involved in launching the inflammatory response, and are key players in adaptive specific immunity.
APOXXIM is a TLR3-ligand that eliminates cancer cells by activating the TLR3 pathway. The platform is manufactured using the TENPORA patented process of Riboxx. Jacques-François Martin, the president of TOLLYS announced:
The potential of TLR3-Ligands such as APOXXIM to treat cancer has been extensively studied by TOLLYS and offer the potential development of a new and unique therapeutic strategy in cancer.”
Riboxx have a lot to show for their platform, and it managed to raise over €1M through Crowdfunding in Germany after being founded in 2009. We also visited Riboxx last year just outside of Dresden (Saxony) on our Labiotech Tour of Northern Germany.
It will be interesting to see whether the APOXXIM program will bring TOLLYS (who don’t yet have a website) to the foreground in the French Biotech ecosystem working on Cancer.